Update on Fiasp insulin 17 August 2023 Diabetes Australia have been consistently talking with both the Federal Government and Novo Nordisk about the need for a solution before 1 October 2023. We have been advised that negotiations are continuing. Both the Government and the manufacturer have been made aware of the significant angst this is causing the diabetes community Diabetes Australia will continue to advocate on this issue. We have set up a page – Fight for Fiasp – where you can lend your voice and advocate on this issue. We will keep you updated, as and when we hear anything on this issue.
News 18 December 2024 Ozempic supply to remain limited in 2025 Ozempic supply will continue to be limited until the end of 2025, according to the latest advice from Novo Nordisk,... Continue Reading
News 16 December 2024 InnoLet human insulin cartridge to be discontinued Novo Nordisk has advised that it will discontinue the Protaphane InnoLet human insulin (rys) 100 IU/mL injection multidose cartridge on... Continue Reading
News 12 December 2024 Expanded access to cheaper medicines for Australians living with type 2 diabetes Diabetes Australia thanks the Albanese Government for its decision to expand the Pharmaceutical Benefits Scheme (PBS) listings for Forxiga® and... Continue Reading